PAFAC (QUINIDINE VS PLACEBO) 2004

A randomised clinical trial investigating the effect of quinidine versus placebo in Persistent AF lasting > 7 days.

### 1 Treatments

<table>
<thead>
<tr>
<th>Studied treatment</th>
<th>Quinidine 0.480 g/d (+ verapamil)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control treatment</td>
<td>placebo</td>
</tr>
</tbody>
</table>

Concomitant treatments: electrical or pharmacological cardioversion, warfarin discretionary

### 2 Patients

<table>
<thead>
<tr>
<th>Patients</th>
<th>Persistent AF lasting &gt; 7 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inclusion criteria</td>
<td>-</td>
</tr>
<tr>
<td>Exclusion criteria</td>
<td>-</td>
</tr>
</tbody>
</table>

### 3 Methods

<table>
<thead>
<tr>
<th>Blinding</th>
<th>double blind</th>
</tr>
</thead>
<tbody>
<tr>
<td>Design</td>
<td>Parallel groups</td>
</tr>
<tr>
<td>Centers</td>
<td>-</td>
</tr>
<tr>
<td>Geographical area</td>
<td>-</td>
</tr>
<tr>
<td>Sample size</td>
<td>465 (377/88)</td>
</tr>
<tr>
<td>ArretTrt1</td>
<td>-</td>
</tr>
<tr>
<td>ArretTrt0</td>
<td>-</td>
</tr>
<tr>
<td>Period_Inclusion</td>
<td>-</td>
</tr>
<tr>
<td>Hypothesis</td>
<td>-</td>
</tr>
</tbody>
</table>
### 4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>HF hospitalization</td>
<td>377</td>
<td>88</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Cardiovascular events</td>
<td>377</td>
<td>88</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Death, unplanned CV hospitalization</td>
<td>377</td>
<td>88</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Stroke</td>
<td>377</td>
<td>88</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>MI</td>
<td>377</td>
<td>88</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Vascular noncardiac death</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Atrial fibrillation recurrence</td>
<td>244</td>
<td>73</td>
<td>0.78</td>
<td>[0.43; 1.41]</td>
</tr>
<tr>
<td>hospitalization for AF</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cardiovascular death</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>non CV death</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all cause mortality</td>
<td>9/377</td>
<td>2/88</td>
<td>1.05</td>
<td>[0.22; 4.95]</td>
</tr>
<tr>
<td>Cardiac nonarrhythmic death</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Withdrawals due to adverse effects</td>
<td>94/377</td>
<td>20/88</td>
<td>1.10</td>
<td>[0.63; 1.90]</td>
</tr>
<tr>
<td>Cardiac arrhythmic death</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Pro-arrhythmia</td>
<td>17/377</td>
<td>2/88</td>
<td>1.98</td>
<td>[0.45; 8.75]</td>
</tr>
</tbody>
</table>

### 5 References


### 6 Comments